Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Validation study of retrospective recall of disease-targeted function: results from the prostate cancer outcomes study.

Legler J, Potosky AL, Gilliland FD, Eley JW, Stanford JL.

Med Care. 2000 Aug;38(8):847-57.

PMID:
10929996
2.

Quality of life after a diagnosis of prostate cancer among men of lower socioeconomic status: results from the Veterans Affairs Cancer of the Prostate Outcomes Study.

Siston AK, Knight SJ, Slimack NP, Chmiel JS, Nadler RB, Lyons TM, Kuzel TM, Moran EM, Sharifi R, Bennett CL; Veterans Affairs Cancer of the Prostate Outcomes Study.

Urology. 2003 Jan;61(1):172-8.

PMID:
12559291
3.

Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer.

Karakiewicz P, Shariat SF, Naderi A, Kadmon D, Slawin KM.

Urology. 2005 Jan;65(1):131-5.

PMID:
15667878
5.
6.

Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study.

Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC.

J Natl Cancer Inst. 2000 Oct 4;92(19):1582-92.

PMID:
11018094
7.

Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function.

Chen RC, Clark JA, Talcott JA.

J Clin Oncol. 2009 Aug 20;27(24):3916-22. doi: 10.1200/JCO.2008.18.6486. Epub 2009 Jul 20.

PMID:
19620493
8.

The validity of prospective and retrospective global change criterion measures.

Schmitt J, Di Fabio RP.

Arch Phys Med Rehabil. 2005 Dec;86(12):2270-6.

PMID:
16344022
9.

Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05.

Feigenberg SJ, Lee WR, Desilvio ML, Winter K, Pisansky TM, Bruner DW, Lawton C, Morton G, Baikadi M, Sandler H.

Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):956-64.

PMID:
15989995
10.

Effect of treatment on quality of life among men with clinically localized prostate cancer.

Schapira MM, Lawrence WF, Katz DA, McAuliffe TL, Nattinger AB.

Med Care. 2001 Mar;39(3):243-53.

PMID:
11242319
11.

Health related quality of life and direct medical care cost in newly diagnosed younger men with prostate cancer.

Jayadevappa R, Bloom BS, Chhatre S, Fomberstein KM, Wein AJ, Malkowicz SB.

J Urol. 2005 Sep;174(3):1059-64; discussion 1064.

PMID:
16094058
12.

Life after radical prostatectomy: a longitudinal study.

Litwin MS, Melmed GY, Nakazon T.

J Urol. 2001 Aug;166(2):587-92.

PMID:
11458073
13.

Should function and bother be measured and reported separately for prostate cancer quality-of-life domains?

Reeve BB, Potosky AL, Willis GB.

Urology. 2006 Sep;68(3):599-603. Epub 2006 Sep 18.

PMID:
16979720
14.

How potent is potent? Evaluation of sexual function and bother in men who report potency after treatment for prostate cancer: data from CaPSURE.

Cooperberg MR, Koppie TM, Lubeck DP, Ye J, Grossfeld GD, Mehta SS, Carroll PR; CaPSURE.

Urology. 2003 Jan;61(1):190-6.

15.
16.
17.

Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls.

Hoffman RM, Gilliland FD, Penson DF, Stone SN, Hunt WC, Potosky AL.

Cancer. 2004 Nov 1;101(9):2011-9.

18.

Recall and attitudes in patients with prostate cancer.

Miles BJ, Giesler B, Kattan MW.

Urology. 1999 Jan;53(1):169-74.

PMID:
9886607
20.

Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study.

Hoffman RM, Barry MJ, Stanford JL, Hamilton AS, Hunt WC, Collins MM.

Am J Med. 2006 May;119(5):418-25.

PMID:
16651054

Supplemental Content

Support Center